Ontology highlight
ABSTRACT:
SUBMITTER: Eskandary F
PROVIDER: S-EPMC5791086 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Eskandary Farsad F Regele Heinz H Baumann Lukas L Bond Gregor G Kozakowski Nicolas N Wahrmann Markus M Hidalgo Luis G LG Haslacher Helmuth H Kaltenecker Christopher C CC Aretin Marie-Bernadette MB Oberbauer Rainer R Posch Martin M Staudenherz Anton A Handisurya Ammon A Reeve Jeff J Halloran Philip F PF Böhmig Georg A GA
Journal of the American Society of Nephrology : JASN 20171214 2
Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m<sup>2</sup> intravenously on days 1, 4, 8, and 11 ...[more]